Publications
Detailed Information
Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Li, Qiang | - |
dc.contributor.author | Kim, You-Seok | - |
dc.contributor.author | An, Ju-Hyun | - |
dc.contributor.author | Kwon, Jin-Ah | - |
dc.contributor.author | Han, Sang-Hyun | - |
dc.contributor.author | Song, Woo-Jin | - |
dc.contributor.author | Youn, Hwa-Young | - |
dc.date.accessioned | 2022-02-16T01:53:05Z | - |
dc.date.available | 2022-02-16T10:54:04Z | - |
dc.date.issued | 2021-10-26 | - |
dc.identifier.citation | BMC Veterinary Research. 2021 Oct 26;17(1):338 | ko_KR |
dc.identifier.issn | 1746-6148 | - |
dc.identifier.uri | https://hdl.handle.net/10371/176959 | - |
dc.description.abstract | Background
Rivoceranib, a novel tyrosine kinase inhibitor, exhibits anti-tumour effects by selectively blocking vascular endothelial growth factor receptor-2 (VEGFR2) in cancer cells. Recently, the therapeutic effects of rivoceranib on solid tumours have been elucidated in human patients. However, the anti-tumour effects of rivoceranib against canine cancer remain unclear. Here, we investigated the anti-tumour effects of rivoceranib using in vitro and in vivo mouse xenograft models. Methods We performed cell proliferation, cell cycle, and migration assays to determine the effects of rivoceranib on canine solid tumour cell lines in vitro. Furthermore, apoptosis and angiogenesis in tumour tissues were examined using a TUNEL assay and immunohistochemistry methods with an anti-cluster of differentiation-31 antibody, respectively. Additionally, the expression levels of cyclin-D1 and VEGFR2 activity were determined using western blot analysis. Results Rivoceranib treatment showed anti-proliferative effects and mediated cell cycle arrest in the canine melanoma cell line (LMeC) and the mammary gland tumour (MGT) cell line (CHMp). In animal experiments, rivoceranib decreased the average volume of LMeC cells compared to that following control treatment, and similar results were observed in CHMp cells. Histologically, rivoceranib induced apoptosis and exerted an anti-angiogenic effect in tumour tissues. It also downregulated the expression of cyclin-D1 and inhibited VEGFR2 activity. Conclusion Our results show that rivoceranib inhibits proliferation and migration of tumour cells. These findings support the potential application of rivoceranib as a novel chemotherapeutic strategy for canine melanoma and MGTs. | ko_KR |
dc.description.sponsorship | This research was supported by Basic Science Research Program to Research Institute for Basic Sciences (RIBS) of Jeju National University through the National Research Foundation of Korea (NRF) funded by the Ministry of Educa‑tion (2019R1A6A1A10072987). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | BMC | ko_KR |
dc.title | Anti-tumor effects of rivoceranib against canine melanoma and mammary gland tumour in vitro and in vivo mouse xenograft models | ko_KR |
dc.type | Article | ko_KR |
dc.contributor.AlternativeAuthor | 김유석 | - |
dc.contributor.AlternativeAuthor | 안주현 | - |
dc.contributor.AlternativeAuthor | 권진아 | - |
dc.contributor.AlternativeAuthor | 한상현 | - |
dc.contributor.AlternativeAuthor | 송우진 | - |
dc.contributor.AlternativeAuthor | 윤화영 | - |
dc.identifier.doi | https://doi.org/10.1186/s12917-021-03026-1 | - |
dc.citation.journaltitle | BMC Veterinary Research | ko_KR |
dc.language.rfc3066 | en | - |
dc.rights.holder | The Author(s) | - |
dc.date.updated | 2021-10-31T04:21:47Z | - |
dc.citation.number | 1 | ko_KR |
dc.citation.startpage | 338 | ko_KR |
dc.citation.volume | 17 | ko_KR |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.